Metsera, Inc. (NASDAQ:MTSR – Get Free Report) dropped 4.8% during mid-day trading on Tuesday . The company traded as low as $25.62 and last traded at $25.91. Approximately 125,837 shares were traded during trading, a decline of 81% from the average daily volume of 650,358 shares. The stock had previously closed at $27.22.
Wall Street Analyst Weigh In
MTSR has been the topic of several analyst reports. Guggenheim started coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 target price on the stock. Cantor Fitzgerald began coverage on shares of Metsera in a research note on Tuesday, February 25th. They set an “overweight” rating on the stock. Evercore ISI assumed coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an “outperform” rating for the company. Finally, Bank of America started coverage on Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 target price on the stock.
Get Our Latest Report on Metsera
Metsera Stock Performance
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Stories
- Five stocks we like better than Metsera
- What is the Nikkei 225 index?
- Tesla Stock: What To Expect With Their Delivery Numbers Report
- What is the S&P 500 and How It is Distinct from Other Indexes
- First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock
- Consumer Staples Stocks, Explained
- Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
